Markets
Pile American money banknote bills with European cash money banknotes, stacks of USA dollars, 100 one hundred dollars and 100 one hundred Euros papers exchange
Getty Images

With another major trade deal signed, can the US dollar get out of its funk?

A long-awaited trade deal with the EU just gave the greenback a lift — but it's a long way back to where it was in January.

Hyunsoo Rim
7/28/25 9:47AM

Two economic heavyweights, which together account for nearly a third of global trade, finally reached a hard-won agreement yesterday — bringing some relief to the market and, perhaps, to the embattled US dollar. 

Starting August 1, a 15% tariff will be applied to most EU exports to the US, including cars, pharmaceuticals, and semiconductors — much less severe than the 30% rate President Trump threatened just weeks ago, though some sector-specific details remain unclear.

With the deal assuaging most investors’ lingering trade concerns, S&P 500 futures ascended to record highs again in early trading, while European stocks gained ~1%. What also ticked up on the news was the beleaguered US dollar, which is coming off the back of its worst first-half performance in more than 50 years.

Dragged down by the “t” word, concerns over the fiscal deficit, and uncertainty over the Fed’s policy direction, the greenback lost ground against almost every major currency this year. Most notably, it dropped a staggering 11% against both the peso and the euro.

Following Sunday’s breakthrough, though, the dollar is showing signs of recovery — gaining 0.7% against the euro and 0.5% against the yen. That rebound could continue, if the pace of last week’s trade deals with Japan, Indonesia, the Philippines, and now the EU, is repeated.

So, who wins from a weaker dollar? Well, your trip to Europe would be more expensive as an American, but your stock portfolio might weirdly benefit — especially in the short term, as a large proportion of America’s largest public companies make their money overseas. Once that revenue is converted into dollars... number go up. Especially for Big Tech.

More Markets

See all Markets
markets

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.